Eisai: Fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA Obtains Additional Approval

TOKYO, Sep 27, 2021 – (JCN Newswire) – AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis and for a new regimen in pediatric patients regarding fully Human Anti-TNFalpha Monoclonal Antibody HUMIRA (generic name, adalimumab [recombinant]; “HUMIRA”).This approval…

Read more

This website is using cookies to improve the user-friendliness. You agree by using the website further.

Privacy policy
Skip to content